Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 4/20 | 0.56 |
| ▸ | CTSK | P43235 | 4/20 | 0.56 |
| ▸ | CTSS | P25774 | 4/20 | 0.56 |
| ▸ | CTSB | P07858 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | STAT3 | P40763 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ROCK2 | O75116 | 8/20 | 0.53 |
| ▸ | ROCK1 | Q13464 | 8/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.50 |
| ▸ | MRE11 | P49959 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6180116 | 0.88 | CTSK (0.56) | CTSLCTSKCTSSCTSBMEN1 | |
| SCHEMBL6184351 | 0.82 | CTSL (0.54) | CTSLCTSKCTSSCTSBMEN1 | |
| SCHEMBL6185021 | 0.81 | MEN1 (0.52) | CTSLCTSKCTSSCTSBMEN1 | |
| SCHEMBL12521541 | 0.80 | CTSL (0.68) | CTSLCTSKCTSSCTSB | |
| SCHEMBL6183599 | 0.80 | CTSL (0.55) | CTSLCTSKCTSSCTSBMAPT | |
| SCHEMBL6184390 | 0.80 | CTSL (0.59) | CTSLCTSKCTSSCTSB | |
| SCHEMBL6180437 | 0.80 | ROCK2 (0.50) | CTSLCTSKCTSSCTSBMEN1 | |
| SCHEMBL21241768 | 0.78 | SCD (0.60) | CTSLCTSKCTSSCTSBMEN1 | |
| SCHEMBL21241787 | 0.78 | SCD (0.60) | CTSLCTSKCTSSCTSBMEN1 | |
| SCHEMBL4714808 | 0.78 | CTSK (0.66) | CTSLCTSKCTSSCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1161415-B1 | N-CYANOMETHYLAMIDES AS PROTEASE INHIBITORS | AXYS PHARM INC (US) | 2005-07-13 | — | — | EP | disclosed |
| US-6593327-B2 | N-cyanomethyl amides which are cysteine protease inhibitors; treating osteoporosis; mixtures with bisphosphonates | AXYS PHARMACEUTICALS, INC. | 2003-07-15 | — | — | US | disclosed |
| US-20030119788-A1 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-06-26 | — | — | US | disclosed |
| US-6476026-B1 | Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2002-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119788-A1 | Novel compounds and compositions as protease inhibitors | CTRL, SERPINB1, CPN1 | CTSL 14/4885CTSK 32/4885CTSS 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.